Abstract
Matrix metalloproteinases (MMPs), are proteinases that participate in extracellular matrix remodelling and degradation. Under normal physiological conditions, the activities of MMPs are regulated at the level of transcription, of activation of the pro-MMP precursor zymogens and of inhibition by endogenous inhibitors (tissue inhibitors of metalloproteinases; TIMPs). Alteration in the regulation of MMP activity is implicated in atherosclerotic plaque development, coronary artery disease and heart failure. The pathological effects of MMPs and TIMPs in cardiovascular diseases involve vascular remodelling, atherosclerotic plaque instability and left ventricular remodelling after myocardial infarction. Since excessive tissue remodelling and increased matrix metalloproteinase activity have been demonstrated during atherosclerotic lesion progression, MMPs represent a potential target for therapeutic intervention aimed at modification of vascular pathology by restoring the physiological balance between MMPs and TIMPs. This review discusses pharmacological approaches to MMP inhibition.
Keywords: Metalloproteinase, tissue inhibitors of metalloproteinases, atherosclerosis, extracellular matrix, degradation, endogenous inhibitors, atherosclerotic plaque, coronary artery disease, vascular remodelling, heart failure, myocardial infarction, vascular pathology, pharmacological approaches to MMP inhibition
Current Topics in Medicinal Chemistry
Title:Novel Therapeutic Approaches Targeting Matrix Metalloproteinases in Cardiovascular Disease
Volume: 12 Issue: 10
Author(s): Alexandros Briasoulis, Dimitris Tousoulis, Nikolaos Papageorgiou, Anna-Maria Kampoli, Emmanuel Androulakis, Charalambos Antoniades, Eleftherios Tsiamis, George Latsios and Christodoulos Stefanadis
Affiliation:
Keywords: Metalloproteinase, tissue inhibitors of metalloproteinases, atherosclerosis, extracellular matrix, degradation, endogenous inhibitors, atherosclerotic plaque, coronary artery disease, vascular remodelling, heart failure, myocardial infarction, vascular pathology, pharmacological approaches to MMP inhibition
Abstract: Matrix metalloproteinases (MMPs), are proteinases that participate in extracellular matrix remodelling and degradation. Under normal physiological conditions, the activities of MMPs are regulated at the level of transcription, of activation of the pro-MMP precursor zymogens and of inhibition by endogenous inhibitors (tissue inhibitors of metalloproteinases; TIMPs). Alteration in the regulation of MMP activity is implicated in atherosclerotic plaque development, coronary artery disease and heart failure. The pathological effects of MMPs and TIMPs in cardiovascular diseases involve vascular remodelling, atherosclerotic plaque instability and left ventricular remodelling after myocardial infarction. Since excessive tissue remodelling and increased matrix metalloproteinase activity have been demonstrated during atherosclerotic lesion progression, MMPs represent a potential target for therapeutic intervention aimed at modification of vascular pathology by restoring the physiological balance between MMPs and TIMPs. This review discusses pharmacological approaches to MMP inhibition.
Export Options
About this article
Cite this article as:
Briasoulis Alexandros, Tousoulis Dimitris, Papageorgiou Nikolaos, Kampoli Anna-Maria, Androulakis Emmanuel, Antoniades Charalambos, Tsiamis Eleftherios, Latsios George and Stefanadis Christodoulos, Novel Therapeutic Approaches Targeting Matrix Metalloproteinases in Cardiovascular Disease, Current Topics in Medicinal Chemistry 2012; 12 (10) . https://dx.doi.org/10.2174/1568026611208011214
DOI https://dx.doi.org/10.2174/1568026611208011214 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Angina in Women without Obstructive Coronary Artery Disease
Current Cardiology Reviews Developing Novel Therapeutic Approaches to Frailty
Current Pharmaceutical Design Clinical Management of Diabetes Mellitus in the Older Adult Patient
Current Diabetes Reviews Applications of Stem Cell Therapy for Physeal Injuries.
Current Stem Cell Research & Therapy Pharmacological Implications of MMP-9 Inhibition by ACE Inhibitors
Current Medicinal Chemistry Peroxisome Proliferator-Activated Receptor ?? (PPAR??) and Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders Angiotensin Type 1 Receptor Blockers in Heart Failure
Current Drug Targets The Role and Therapeutic Potential of Ser/Thr Phosphatase PP2A in Apoptotic Signalling Networks in Human Cancer Cells
Current Molecular Medicine SnoN in TGF-β Signaling and Cancer Biology
Current Molecular Medicine Psychological Stress in Pathogenesis of Essential Hypertension
Current Hypertension Reviews Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges
Current Vascular Pharmacology Influence of Statin Use on Endothelial Function: From Bench to Clinics
Current Pharmaceutical Design Caveolin-1: A Promising Therapeutic Target for Diverse Diseases
Current Molecular Pharmacology The Mechanism of Carvedilol in Experimental Viral Myocarditis
Current Pharmaceutical Design The Applications of Targeting Anti-Cancer Agents in Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry OPA1 in Cardiovascular Health and Disease
Current Drug Targets Glibenclamide Action on Myocardial Function and Arrhythmia Incidence in the Healthy and Diabetic Heart
Cardiovascular & Hematological Agents in Medicinal Chemistry Angiotensin II Receptor Blocker: Possibility of Antitumor Agent for Prostate Cancer
Mini-Reviews in Medicinal Chemistry GPER/GPR30 and Regulation of Vascular Tone and Blood Pressure
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) APE1/Ref-1Role in Redox Signaling: Translational Applications of Targeting the Redox Function of the DNA Repair/Redox Protein APE1/Ref-1
Current Molecular Pharmacology